FUNDAMENTALS · Fundamentals · CN Healthcare

Edding Genor Group Holdings (6998) Fundamentals 2026 — P/E 7.0x, Revenue Analysis | SniperIQ

Edding Genor Group Holdings (6998) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK

.0B, trading at HK
.91 on the HKSE. This SniperIQ fundamentals page covers Edding Genor Group Holdings's valuation (P/E 7.0x, P/B 0.6x), profitability (net margin 16.1%), revenue (¥2.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
.0B
P/E (TTM)7.0x
Net Margin16.1%
Revenue (FY25)¥2.7B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Edding Genor Group Holdings's market cap?

Edding Genor Group Holdings (6998) has a market capitalization of approximately HK

.0B, trading at HK
.91 on the HKSE. Market cap moves with the live share price.

What is Edding Genor Group Holdings's P/E ratio?

Edding Genor Group Holdings's trailing twelve-month P/E ratio is 7.0x, with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Edding Genor Group Holdings?

Edding Genor Group Holdings runs a net profit margin of 16.1%, a gross margin of 68.0%, and an operating margin of 28.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Edding Genor Group Holdings generate?

Edding Genor Group Holdings reported revenue of ¥2.7B for fiscal year 2025, with net income of ¥433M and earnings per share (EPS) of 0.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Edding Genor Group Holdings pay a dividend?

Edding Genor Group Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Edding Genor Group Holdings financially healthy?

Edding Genor Group Holdings carries a debt-to-equity ratio of 0.39x and a current ratio of 1.00x, with a market beta of 0.88. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Edding Genor Group Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Edding Genor Group Holdings (6998) the key facts are: market cap HK

.0B, P/E 7.0x, revenue ¥2.7B, 52-week range 1.54-3.64. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Edding Genor Group Holdings's full fundamentals live

Get Edding Genor Group Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Pacira BioSciences (PCRX) fundamentals · Beijing Airdoc Technology (2251) fundamentals · ETHK Labs (1931) fundamentals · Olema Pharmaceuticals (OLMA) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons